Hyperhomocysteinemia as a risk factor for venous thrombosis

Area of Science:

• Cardiovascular Medicine
• Genetics
• Hematology

Background:

• Classical homocystinuria is linked to arterial and venous vascular diseases.
• Emerging evidence suggests mild hyperhomocysteinemia is a risk factor for venous thrombosis.
• The methylenetetrahydrofolate reductase (MTHFR) 677C-->T mutation causes mild hyperhomocysteinemia but isn't a confirmed thrombosis risk.

Purpose of the Study:

• To review the current understanding of hyperhomocysteinemia and venous thrombosis.
• To explore potential pathophysiological mechanisms linking mild hyperhomocysteinemia to venous thrombosis.
• To discuss the clinical implications for managing patients with venous thrombosis and elevated homocysteine levels.

Main Methods:

• Literature review of studies on hyperhomocysteinemia, MTHFR gene, and venous thrombosis.
• Analysis of proposed pathophysiological mechanisms for vascular disease in hyperhomocysteinemia.
• Discussion of conflicting findings regarding thrombotic risk factors and hyperhomocysteinemia.

Main Results:

• Mild hyperhomocysteinemia is increasingly recognized as a risk factor for venous thrombosis.
• The MTHFR 677C-->T polymorphism is a common cause of mild hyperhomocysteinemia but its role in venous thrombosis is uncertain.
• Pathophysiological models for venous thrombosis in mild hyperhomocysteinemia are still developing.

Conclusions:

• Clinicians may consider homocysteine measurement in patients with venous thrombosis, especially when screening for thrombophilia.
• Vitamin supplementation may be considered for elevated homocysteine levels, but its benefits require further clinical validation.
• Patients should be informed about the uncertainties surrounding the efficacy of vitamin supplementation in managing hyperhomocysteinemia-related venous thrombosis.